Lafadera

Dimethyl fumarate, the active ingredient in Lafadera, is an immunomodulating agent presented as an oral tablet for oral use. It is employed in the management of relapsing forms of multiple sclerosis in adult patients and works by modulating immune responses to reduce inflammatory activity associated with disease progression.

GNH USA supplies Lafadera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across global markets.

Lafadera (dimethyl fumarate) is used within the disease‑modifying therapy class for multiple sclerosis and related demyelinating conditions.

- Relapsing‑Remitting Multiple Sclerosis: reduces the frequency of clinical relapses and slows disability progression. - Clinically Isolated Syndrome: delays conversion to clinically definite multiple sclerosis. - Secondary Progressive Multiple Sclerosis with active disease: may lower relapse rates and modestly impact disease activity.

Dimethyl fumarate is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Flushing: transient redness and warmth, often mild to moderate. - Gastrointestinal discomfort: includes nausea, abdominal pain, and diarrhea. - Lymphopenia: reduction in peripheral lymphocyte count, typically mild.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Severe infections: increased susceptibility to opportunistic infections. - Hepatic injury: elevated liver enzymes or hepatitis. - Anaphylaxis: rare severe allergic reaction requiring immediate medical attention. - Severe lymphopenia: profound reduction in lymphocytes increasing infection risk.

Prior to initiating therapy, clinicians should evaluate patient-specific factors and monitor ongoing safety parameters.

- Monitor lymphocyte counts: baseline and periodic testing recommended to detect lymphopenia. - Assess hepatic function: check liver enzymes before starting and during treatment. - Avoid in patients with active infections: defer therapy until infection resolves. - Pregnancy and breastfeeding: consider only if potential benefits outweigh risks; data are limited. - Review concomitant immunosuppressants: increased infection risk may necessitate dose adjustments. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Dimethyl fumarate may interact with several medications, requiring careful assessment.

Major Interactions (Avoid): - Live vaccines: contraindicated during treatment due to impaired immune response. - Other immunosuppressive agents: may amplify infection risk. - Drugs causing severe lymphopenia: concurrent use should be avoided.

Moderate Interactions (Monitor Closely): - Antacids: may affect absorption; separate dosing by at least 2 hours. - Carbamazepine: may reduce dimethyl fumarate plasma levels. - Warfarin: monitor INR as potential alteration of anticoagulant effect.